Max Wallace, CEO of Accelerate Brain Cancer Cure, presented a talk on "Personalized Precision Medicine and Molecular Genomics" at the Congress of Neurological Surgeons (CNS) Annual Meeting in San Francisco.
Key industry and foundation leaders were invited to share their disruptive ideas on the future of neurosurgery at the new CNS Neurosurgery Innovations Symposium. "We were very pleased to have Max participate in this new symposium," said Steven Kalkanis, National Executive Committee member of CNS, "especially given all the groundbreaking and exciting work being done at ABC2."
Other topics included the future of extracellular exosome vesicles and prescreening biomarkers, advances in molecular and functional imaging along with intraoperative MRI and navigation, and finally, laser-induced thermotherapy.
A panel of neurosurgery experts, including Bob Carter, UCSD; Nino Chiocca, Dana Farber/Brigham and Womens and Mark Rosenblum, Henry Ford Hospital, moderated the program and encouraged dialogue among participants and panelists to collectively push the field forward.
The Congress of Neurological Surgeons is the largest neurosurgical society in the world and the global leader in neurosurgical education, serving to promote health by advancing neurosurgery worldwide through innovation and excellence in education. With more than 8,000 members worldwide, the CNS provides global leadership in neurosurgery by inspiring and facilitating scientific discovery and its translation into clinical practice.